National Pension Service lifted its stake in shares of Abbott Laboratories (NYSE:ABT) by 3.7% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,408,690 shares of the healthcare product maker’s stock after buying an additional 49,826 shares during the period. National Pension Service’s holdings in Abbott Laboratories were worth $80,394,000 at the end of the most recent quarter.

Several other large investors also recently made changes to their positions in ABT. Eagle Ridge Investment Management boosted its position in shares of Abbott Laboratories by 5.2% during the second quarter. Eagle Ridge Investment Management now owns 197,488 shares of the healthcare product maker’s stock valued at $8,849,000 after buying an additional 9,760 shares during the last quarter. Callahan Advisors LLC boosted its position in shares of Abbott Laboratories by 13.8% during the second quarter. Callahan Advisors LLC now owns 93,985 shares of the healthcare product maker’s stock valued at $4,569,000 after buying an additional 11,412 shares during the last quarter. Retirement Systems of Alabama boosted its position in shares of Abbott Laboratories by 0.5% during the second quarter. Retirement Systems of Alabama now owns 1,309,756 shares of the healthcare product maker’s stock valued at $63,667,000 after buying an additional 6,070 shares during the last quarter. Chicago Partners Investment Group LLC boosted its position in Abbott Laboratories by 124.1% in the second quarter. Chicago Partners Investment Group LLC now owns 15,237 shares of the healthcare product maker’s stock worth $688,000 after purchasing an additional 8,437 shares during the last quarter. Finally, Palladium Partners LLC boosted its position in Abbott Laboratories by 0.6% in the second quarter. Palladium Partners LLC now owns 54,242 shares of the healthcare product maker’s stock worth $2,637,000 after purchasing an additional 304 shares during the last quarter. 70.61% of the stock is currently owned by institutional investors.

Abbott Laboratories (ABT) opened at $57.64 on Wednesday. Abbott Laboratories has a 1 year low of $42.31 and a 1 year high of $64.60. The company has a debt-to-equity ratio of 0.72, a quick ratio of 2.26 and a current ratio of 2.69. The company has a market capitalization of $99,927.90, a price-to-earnings ratio of 22.96, a PEG ratio of 1.72 and a beta of 1.55.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings results on Wednesday, January 24th. The healthcare product maker reported $0.74 EPS for the quarter, beating analysts’ consensus estimates of $0.73 by $0.01. Abbott Laboratories had a return on equity of 13.80% and a net margin of 1.74%. The firm had revenue of $7.59 billion for the quarter, compared to analysts’ expectations of $7.38 billion. During the same quarter in the prior year, the firm earned $0.65 EPS. The business’s revenue for the quarter was up 42.3% compared to the same quarter last year. sell-side analysts forecast that Abbott Laboratories will post 2.86 earnings per share for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Thursday, February 15th. Stockholders of record on Friday, January 12th will be given a dividend of $0.28 per share. This represents a $1.12 dividend on an annualized basis and a dividend yield of 1.94%. The ex-dividend date of this dividend is Thursday, January 11th. This is a boost from Abbott Laboratories’s previous quarterly dividend of $0.27. Abbott Laboratories’s dividend payout ratio is currently 430.79%.

In other news, insider Brian J. Blaser sold 23,866 shares of the company’s stock in a transaction on Friday, November 17th. The stock was sold at an average price of $55.55, for a total transaction of $1,325,756.30. Following the transaction, the insider now owns 146,387 shares of the company’s stock, valued at approximately $8,131,797.85. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Stephen R. Fussell sold 13,313 shares of the company’s stock in a transaction on Tuesday, January 30th. The shares were sold at an average price of $62.84, for a total value of $836,588.92. Following the transaction, the executive vice president now directly owns 152,343 shares in the company, valued at approximately $9,573,234.12. The disclosure for this sale can be found here. Insiders have sold a total of 374,458 shares of company stock worth $20,752,706 in the last ninety days. Insiders own 0.76% of the company’s stock.

Several research firms have weighed in on ABT. BMO Capital Markets boosted their price objective on Abbott Laboratories from $65.00 to $70.00 and gave the stock an “outperform” rating in a research report on Thursday, January 25th. Stifel Nicolaus boosted their price objective on Abbott Laboratories from $58.00 to $63.00 and gave the stock a “buy” rating in a research report on Thursday, October 19th. Bank of America boosted their price objective on Abbott Laboratories from $60.00 to $70.00 in a research report on Wednesday, January 24th. They noted that the move was a valuation call. JPMorgan Chase & Co. boosted their price objective on Abbott Laboratories from $65.00 to $69.00 and gave the stock an “overweight” rating in a research report on Thursday, January 25th. Finally, Leerink Swann reissued a “market perform” rating and issued a $68.00 price objective (up previously from $60.00) on shares of Abbott Laboratories in a research report on Thursday, January 25th. Eight equities research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the stock. The company has an average rating of “Buy” and a consensus price target of $65.47.

ILLEGAL ACTIVITY WARNING: “National Pension Service Has $80.39 Million Position in Abbott Laboratories (ABT)” was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece on another website, it was illegally stolen and reposted in violation of US & international copyright & trademark laws. The correct version of this piece can be read at https://www.thecerbatgem.com/2018/02/14/national-pension-service-has-80-39-million-position-in-abbott-laboratories-abt.html.

Abbott Laboratories Profile

Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States.

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT).

Institutional Ownership by Quarter for Abbott Laboratories (NYSE:ABT)

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.